Quantcast

Latest glioblastoma Stories

2010-12-23 16:54:43

A study fast-tracked for online publication Dec. 22 in the New England Journal of Medicine has identified an important gene deletion in up to one of every four cases of glioblastoma, the most common adult brain cancer. This deletion contributes to tumor development, promotes resistance to therapy and considerably worsens a patient's survival prospects. The deletion of the gene, known as NFKBIA, triggers biochemical processes similar to those resulting from a better-known aberration common in...

2010-10-01 14:08:31

Discovery shows that activating rearrangements in receptor genes are more common than previously thought A multi-institutional team led by investigators from Memorial Sloan-Kettering Cancer Center has published a study that provides new insight into genetic changes that make some forms of glioblastoma, the most common type of primary brain cancer, more aggressive than others and explains why they may not respond to certain therapies. The research was led by senior author Eric C. Holland, MD,...

2010-04-13 14:25:35

Scientists publish new findings on glioblastoma, a tumor particularly difficult to treat Glioblastoma is a guileful enemy. While most of the brain tumor can often be removed surgically, in virtually every case the tumor reappears. One reason for this is that sporadic, infiltrative tumor cells will remain in the brain even after most careful surgery. Researchers at the University of Bonn have now subjected these 'forgotten' cells to closer scrutiny for the first time. While doing this, they...

2010-04-01 13:38:46

Scientists at the German Cancer Research Center discover key molecule for cancer initiation The "cradle" of new neurons in the adult brain is well known. It is what is called the subventricular zone, a tissue structure lining the lateral ventricles. This is where neural or brain stem cells reside, which are responsible for generating new neurons if needed. For many years now, the subventricular zone has been suspected to be the origin of specific malignant brain tumors called gliomas, the...

01f4bb9e753b894edfd2966a7a0abffe1
2010-02-26 09:40:00

Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells "“ a small population of cells within tumors that perpetuate cancer growth "“ conclude that blocking these cells may be somewhat effective, but more than one targeted drug attack may be needed to get the job done. One focus of attack is a chemical pathway within stem cells known as Notch, which scientists have shown is important for cancer stem cell growth.  A new...

2010-01-11 06:00:00

RICHMOND, Calif., Jan. 11 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as well as the renewal of $3.0 million in funding for the Phase 2b trial by the Juvenile Diabetes Research Foundation International (JDRF). Edward Lanphier, Sangamo's president and CEO, will provide an update on the company's ZFP Therapeutic(TM)...

2009-12-23 17:23:43

Discovery made using new systems biology method, which enabled the scientists to pinpoint the genes from a mass of data A team of Columbia scientists have discovered two genes that, when simultaneously activated, are responsible for the most aggressive forms of human brain cancer. This finding was made possible by the assembly of the first comprehensive network of molecular interactions that determine the behavior of these cancer cells, a map so complex and elusive that, until now, it could...

86fb375d9b7810c2b867e5e09ded0a2f1
2009-11-30 14:17:15

The University of Navarra Hospital has launched a series of clinical trials in order to assess the efficacy of an immunotherapy treatment. This approach involves the application of personalized vaccines "”produced from healthy and tumor cells from the patient him or herself"” and designed to combat glioblastomas, one of the most aggressive and frequent malignant tumors. The new therapy is administered to participating patients combined with the standard, first-line treatment...

2009-09-02 06:30:00

BOSTON, Mass. and TUSTIN, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara(R) appeared well tolerated and demonstrated encouraging signs of efficacy in patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. The data from an ongoing Phase II study of Cotara in patients with recurrent GBM is being...

2009-07-31 08:44:46

Cancer researchers at Georgetown University's Lombardi Comprehensive Cancer Center have successfully tested a small, engineered antibody they say shuts down growth of human glioblastoma tumors in cell and animal studies. Glioblastoma is the deadliest of brain cancers; there is no effective treatment.In the current online issue of the journal Oncogene, the researchers demonstrate how this antibody latches onto a receptor that studs the outside of glioblastoma cells, preventing a growth factor...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related